FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of the formula (I) or to its pharmaceutically acceptable salt, where R1 is C1-6alkyl; X is NRa; Y is CRbRc or NRd, in which Rc is H, N(CH3)2, Rb, together with Ra, carbon atom related to Rb, and nitrogen atom related to Ra, is piperidinyl, and Rd, together with Ra and nitrogen atoms related to Rd and Ra, is piperazinyl; R2 is -CH2CH2Re or NRfRg, in which Re is H, halogen or ORh, and each of Rf and Rg is C1-6alkyl, Rh is H, and R3 is pyridyl or pyrimidinil. The invention also relates to a pharmaceutical composition for the treatment of cancer associated with tyrosine kinase, based on the compound of the formula (I).
EFFECT: new compounds and a pharmaceutical composition based on them are obtained that can be used in medicine for the treatment of cancer.
13 cl, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDAZOPYRIDINE COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2782743C2 |
| POLYMORPHOUS FORM OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITOR AND METHOD OF ITS OBTAINING | 2012 |
|
RU2491286C1 |
| DIHYDROBENZODIAZEPINES, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2000 |
|
RU2247115C2 |
| MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
| METHOD OF PRODUCING 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | 2008 |
|
RU2456285C2 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION | 2018 |
|
RU2756055C2 |
| CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM | 2018 |
|
RU2795146C2 |
| HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2764243C2 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | 2016 |
|
RU2718915C2 |
| OESTROGEN RECEPTOR MODULATING COMPOUNDS | 2019 |
|
RU2826635C2 |
